|Bid||2.7400 x 800|
|Ask||2.7500 x 1800|
|Day's Range||2.6200 - 2.8100|
|52 Week Range||2.1500 - 6.3000|
|Beta (3Y Monthly)||2.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Company Cuts Selected Early-Stage R&D Programs, Burn-Rate by 25%, and Staff by 28% Management to Host Conference Call on July 17 at 8:00 AM EDT PLYMOUTH MEETING, Pa. , July 16, 2019 /PRNewswire/ -- Inovio ...
PLYMOUTH MEETING, Pa., July 10, 2019 /PRNewswire/ -- Geneos Therapeutics, a clinical-stage biotech company, a spin-out of Inovio Pharmaceuticals (INO), announced today that the first cancer patient was dosed using the company's GT-EPIC Neoantigen-Targeting Personalized Vaccine Technology. In this first-in-human treatment – part of a clinical collaboration between Geneos and Washington University School of Medicine in St. Louis – a patient with Anaplastic Astrocytoma, a form of advanced brain cancer, is being treated on a Compassionate Use basis with the patient's own tumor-derived neoantigen vaccine.
PLYMOUTH MEETING, Pa., July 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia (VIN). VGX-3100 is an immunotherapy that targets human papillomavirus (HPV) 16 and 18 and is being studied for the treatment of HPV-related precancerous lesions and the HPV infection that causes these lesions. Inovio is already evaluating VGX-3100 in two Phase 3 registration trials (REVEAL 1 and REVEAL 2) to treat cervical dysplasia caused by HPV.
PLYMOUTH MEETING, Pennsylvania, June 26, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) today announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial ("REVEAL 1") of VGX-3100, a novel DNA-based immunotherapy being tested to treat cervical dysplasia caused by human papillomavirus (HPV). Left untreated, cervical dysplasia can progress to cervical cancer. If approved, VGX-3100 would be the first immunotherapy and non-surgical alternative for women with late-stage cervical dysplasia.
PLYMOUTH MEETING, Pennsylvania, June 10, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that the medical arm of the U.S. Defense Threat Reduction Agency (DTRA) will fund the further development of Inovio's new commercial intradermal delivery device. DTRA's Medical CBRN Defense Consortium will provide $8.14 million to support Inovio in developing a small, portable, battery-powered intradermal device branded as CELLECTRA® 3PSP to be used in the administration of Inovio's vaccines and therapies which include DTRA developed products.
PLYMOUTH MEETING, Pa. and OSLO, Norway, May 21, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO), together with CEPI, today announced it has dosed subjects in a Phase 1, first-in-human clinical trial to evaluate INO-4500, its DNA candidate vaccine to prevent infection from the Lassa virus. Inovio plans to enroll approximately 60 volunteers in this placebo controlled, blinded, dose escalation study evaluating INO-4500 for safety, tolerability and immune responses. This Inovio trial represents the first Lassa candidate vaccine to enter the clinic.
Frankfurt Prime Standard: QIA) today announced a collaboration to co-develop a diagnostic test to identify patients most likely to respond to VGX-3100, Inovio's immunotherapy to treat advanced cervical dysplasia associated with the human papillomavirus virus (HPV). This precision medicine partnership focuses on Inovio's VGX-3100, a late-stage product candidate currently in two pivotal Phase 3 clinical trials (REVEAL 1 and 2) with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus.
PLYMOUTH MEETING, Pa. and SEOUL, South Korea, May 15, 2019 /PRNewswire/ -- Inovio Pharmaceuticals Inc. (INO) and Plumbline Life Sciences (XKRX:222670) today announced a collaboration to co-develop a novel animal health vaccine for African swine fever (ASF) virus. The vaccine will be developed using Inovio's SynCon® technology and delivered using CELLECTRA® efficacy-enabling devices. Plumbline, based in South Korea, will fund all development and commercialization of the ASF vaccine.
PLYMOUTH MEETING, Pa. , May 9, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO), an innovative biotechnology company focused on the discovery, development and commercialization of its synthetic ...
PLYMOUTH MEETING, Pa. , May 6, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that its lead Phase 3 product candidate, VGX-3100, has been granted an Advanced Therapy Medicinal ...
PLYMOUTH MEETING, Pa., May 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that first quarter 2019 financial results will be released after the market close on May 9, 2019. Following the release, the Company will host a conference call and live webcast at 4:30 p.m. ET, to provide a general business update and financial results for the first quarter 2019. Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines that transform the treatment and prevention of cancer and infectious disease. Inovio's proprietary technology platform applies antigen sequencing and DNA delivery to activate potent immune responses to targeted diseases. The technology functions exclusively in vivo, and has been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens.
PLYMOUTH MEETING, Pa., April 18, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today the company's novel DNA-encoded Bi-specific T Cell Engagers (dBiTEs) generated potent anti-tumor activities and cleared established tumors in preclinical studies. Inovio's dBiTE results were published in a JCI Insight article entitled, "DNA-encoded bi-specific T cell engagers and antibodies present long-term antitumor activity," by Inovio and its collaborators at The Wistar Institute. JCI Insight is a peer-reviewed journal published by the American Society for Clinical Investigation dedicated to well-executed preclinical and clinical research studies.
PLYMOUTH MEETING, Pa., April 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that VGX-3100, its Phase 3 immunotherapy to treat cervical dysplasia, was recognized as "Best Therapeutic Vaccine" at the World Vaccine Congress held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards honor outstanding vaccine and immunotherapy advancements and achievements across the worldwide industry as judged by a panel of global biotech industry stakeholders. Dr. J. Joseph Kim, President and CEO, said, "We greatly appreciate the World Vaccine Congress' recognition of Inovio's breakthrough immunotherapy VGX-3100 that could offer the first non-surgical treatment to patients who are suffering from HPV-related pre-cancers that often progress to cancer.
PLYMOUTH MEETING, Pa. , April 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it achieved a third indication milestone from AstraZeneca resulting from dosing a patient ...
PLYMOUTH MEETING, Pennsylvania, April 3, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) today announced its novel therapy INO-3106 against the human papilloma virus type 6 (HPV 6) demonstrated clinical efficacy in a study of two patients with recurrent respiratory papillomatosis (RRP). RRP is an HPV-associated disease that can cause noncancerous tumor growths leading to life-threatening airway obstructions, and occasionally progresses to cancer. RRP is primarily caused by two strains of HPV, HPV 6 and 11, which also predominantly cause genital warts.
PLYMOUTH MEETING, Pennsylvania, April 2, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today the company's novel DNA-Encoded Bi-specific T Cell Engagers (dBiTEs™) generated potent anti-tumor activities in a preclinical study. For this study, Inovio, with its collaborators at The Wistar Institute, developed a novel dBiTE targeting the HER2 molecule which was tested in therapeutic models for the treatment of ovarian and breast cancers. Importantly, just a single dose of Inovio's HER2 dBiTE resulted in high levels of corresponding BiTE in mice for four months, far exceeding what is typically displayed with conventional BiTE's short half-life of only a few hours.